<p>In clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. Other are:</p>

<ul>
	<li>Anaphylaxis&nbsp;</li>
	<li>Residual paralysis&nbsp;</li>
	<li>Myopathy&nbsp;</li>
	<li>Increased pulmonary vascular resistance</li>
</ul>

<p>Although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including Rocuronium Bromide, have been reported. Anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse - shock), and cutaneous changes (e.g. angioedema, urticaria). These reactions have, in some cases, been fatal. Due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.&nbsp;<br />
<br />
Since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematosus reactions at the site of injection and/or generalized histaminoid (anaphylactoid) reactions (see also under Anaphylactic Reactions above) should always be taken into consideration when administering these agents.&nbsp;In clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3 0.9mg/kg Rocuronium Bromide.<br />
<br />
<strong>Prolonged neuromuscular block</strong>: The most frequent adverse reaction to nondepolarizing blocking agents as a class consists of an extension of the agent&#39;s pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnoea.&nbsp;<br />
<br />
<strong>Myopathy</strong>: Myopathy has been reported after the use of various neuromuscular blocking agents in the ICU in combination with corticosteroids.<br />
<br />
<strong>Local injection site reactions</strong>: During rapid sequence induction of anesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. In clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anesthesia with fentanyl and thiopental.</p>